We are thankful to our funding agencies for their support:

Deutsche Krebshilfe


A MultIceNTer PhasE I RNA VaCcine Trial to Exploit NeoePitope-Specific T Cells for the Treatment of H3K27M-Mutated Gliomas – (INTERCEPT H3). 2019 - 2023

Regulation of tumor immunity through the integrated stress response (ISR) in myeloid cells. 2019 - 2021



Helmholtz Gemeinschaft


Helmholtz Zukunftsthema Immunologie und Infektion, WP3: Innovative Therapies. 2017 - 2020

Else Kröner-Fresenius-Stiftung


Mechanismen hirntumorreaktiver T-Helferzellen im Kontext immuntherapeutischer Interventionen. 2019 - 2021

Imaging von Immunantworten und Tumorzellinvasion in Gliom Modellen. 2019 - 2021

Deutsches Konsortium für Translationale Krebsforschung

TCR Proof of Concept in cooperation with NCT (TCR-POC)

AMPLIFYing NEOepitope-specific VACcine Responses in progressive diffuse glioma – a randomized, open label, 3 arm multicenter Phase I trial (AMPLIFY-NEOVAC, NOA-21)

Targeting IDH1R132H in WHO grade III-IV IDH1R132H-mutated gliomas by a peptide vaccine - a Phase I safety, tolerability and immunogenicity multicenter trial (NOA-16)

CAR2Brain_Immune Response CAR-NK Immunotherapy in Glioblastoma_DKTK Joint Funding “UPGRADE”. 2020 - 2024

Baden Württemberg Stiftung


REsolvInG ImmuNITy to targEt Brain Tumors (RE-IGNITE). 2020 - 2023

Deutsche Forschungsgemeinschaft


Understanding and targeting resistance in glioblastoma. CRC UNITE 1389. 2019 - 2023

Vascular control of tumor immunity in the CNS. CRC1366. 2019 - 2022

Hallmarks of Skin Cancer, Tumor Microenvironment and Melanoma Immunity, Response and Resistance to Checkpoint Blockade in melanoma brain metastases. CRC RTG2099. 2019 - 2024

Impact of dietary tryptophan on the gut microbiome and autoimmune neuroinflammation. 2018 - 2020. 

Schwiete Stiftung


Maßgeschneiderte Immuntherapie von Patienten mit Hirntumoren. 2017 - 2020



The role of CXCL10 in the immune regulation of melanoma and glioma. 2019 - 2022

Swiss Cancer League, the Swiss Cancer Research foundation and the Union for International Cancer Control (UICC)


Swiss Bridge Award 2019 - Rational design of inhibitory chimeric antigen receptor (iCAR) to prevent anti CD19 CAR-T cell related neurotoxicity in B-cell malignancies. 2019 - 2022

Hertie Stiftung


Hertie Academy of clinical neuroscience als Kristallisationspunkt für ein Hertie Network of Excellence in clinical neuriscience. 2019 - 2022

nach oben
powered by webEdition CMS